Berenberg initiated coverage of Evotec (EVO) with a Buy rating and EUR 10 price target The firm says the company benefits from a “leading position in important fields” such as drug discovery based on induced pluripotent stem cells, as well as the shift to continuous manufacturing and favorable underlying market trends.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVO:
- Evotec Discloses Increased Goldman Sachs Stake After Crossing Voting-Rights Threshold
- Evotec Reports New 5.03% Major Shareholding via Shares and Equity Swaps
- Evotec’s Just – Evotec Biologics Wins Gates Foundation Grant to Advance AI-Optimised Affordable Biologics
- Evotec Discloses Increased JPMorgan Stake After Major Holdings Notification
- Evotec Names Sarah Fakih EVP to Lead Integrated Global Communications and Investor Relations